EH3A Amarin Corporation Plc Sponsored ADR

Latest Research Evaluating VASCEPA® (Icosapent Ethyl) Mechanisms of Action Presented at European Atherosclerosis Society (EAS) Congress 2020

Latest Research Evaluating VASCEPA® (Icosapent Ethyl) Mechanisms of Action Presented at European Atherosclerosis Society (EAS) Congress 2020
EN
05/10/2020

Underlying

EH3AAmarin Corporation Plc Sponsored ADR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amarin Corporation Plc Sponsored ADR

 PRESS RELEASE
Free
EH3A Amarin Corporat...

Amarin Announces Exclusive License and Supply Agreement with Recordati...

Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe -- Company to Streamline Global Operations, Resulting in Approximately $70 Million of Cost Savings Over Next 12 Months and Accelerated Path to Positive Cash Flow -- -- Conference Call Today at 8:00 a.m. EDT with Investor Materials Available at AdvancingAmarin.com -- DUBLIN, Ireland and BRIDGEWATER, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation (NASDAQ: AMRN) today announced that the Company has entered into an exclusive long-term license and supply ag...

June 24, 2025 1 EN
 PRESS RELEASE
Free
EH3A Amarin Corporat...

Amarin Reports First Quarter 2025 Financial Results

Amarin Reports First Quarter 2025 Financial Results -- First Quarter 2025 Performance Reflects Contribution from Multiple Revenue Streams Across Geographies, Efforts to Support Strong Balance Sheet and Continued Strategic Execution to Maximize Global Value of VASCEPA®/VAZKEPA® -- -- Nasdaq Listing Compliance Regained Following Completed 1-For-20 ADS Ratio Change -- -- Company to Host Conference Call Today at 8:00 a.m. EDT -- DUBLIN and BRIDGEWATER, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today announced financial results for the first quarter of 20...

May 7, 2025 1 EN
 PRESS RELEASE
Free
EH3A Amarin Corporat...

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement -- Nasdaq Compliance Follows ADS Ratio Change to Secure Company’s Public Listing -- -- Amarin Remains Focused on Maximizing the Global Value of VASCEPA/VAZKEPA – DUBLIN and BRIDGEWATER, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced it has regained compliance with the Nasdaq Stock Market (“Nasdaq”) continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications. On April 29, 2025, the Company received confirmation from ...

April 29, 2025 1 EN
 PRESS RELEASE
Free
EH3A Amarin Corporat...

Amarin to Report First Quarter 2025 Financial Results and Host Confere...

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 DUBLIN and BRIDGEWATER, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its first quarter 2025 results followed by Q&A on Wednesday, May 7th, 2025, at 8:00 a.m. ET. The conference call with management will follow the release of the Company’s first quarter 2025 financial results in the pre-market hours on May 7th. Confer...

April 28, 2025 1 EN
 PRESS RELEASE
Free
EH3A Amarin Corporat...

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change Action Taken to Maintain Company’s Nasdaq Listing DUBLIN and BRIDGEWATER, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today confirmed that April 11, 2025 will be the effective date for the Company’s previously announced Ratio Change on its American Depositary Shares (“ADS”) -- an action in which the Company will effect a ratio change from one (1) ADS representing one (1) ordinary share to a new ratio of one (1) ADS representing twenty (20) ordinary shares (the "Ratio Change"). The objective...

April 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch